Want to hire this expert for a project? Request a quote for free.
Profile Details
Create Project
USD 200 /hr
Hire Dr. Sasha B.
United States
USD 200 /hr
MD/PhD/MBA | Translational Research, Clinical Development & Trial Design: Neurology, Immunology, Genetics & Rare Diseas
Profile Summary
Subject Matter Expertise
Services
Writing
Clinical Trial Documentation,
Medical Writing,
Non-Medical Regulatory Writing,
Technical Writing,
Business & Legal Writing,
Copywriting,
Creative Writing,
Newswriting,
General Proofreading & Editing,
Translation
Research
Meta-Research,
Feasibility Study,
Fact Checking,
Gap Analysis,
Gray Literature Search,
Scientific and Technical Research,
Systematic Literature Review,
Secondary Data Collection
Consulting
Business Strategy Consulting,
Healthcare Consulting,
Scientific and Technical Consulting
Data & AI
Statistical Analysis,
Image Processing,
Image Analysis,
Data Visualization,
Big Data Analytics,
Data Mining,
Data Cleaning,
Data Processing,
Data Insights
Product Development
Concept Development,
Product Launch Support
Work Experience
Executive Director
Capsida Biotherapeutics (United States)
August 2025 - December 2025 
Senior Director
Keros Therapeutics
March 2024 - August 2025
Associate Medical Director
Atara Biotherapeutics (United States)
July 2021 - January 2024
Senior/Medical Science Liaison
EMD Serono, Inc. (United States)
January 2019 - July 2021
Neuroscience and Neurology
IQVIA (United States)
October 2017 - January 2019
Res. Assistant Professor / Sr. Consultant
Northwestern Medicine
October 2014 - October 2017
Postdoctoral Researcher
University of Chicago
October 2013 - October 2014
Instructor
Roosevelt University
October 2013 - June 2014
Postdoctoral Fellow
University of Kentucky
January 2010 - September 2013
Postdoctoral Fellow/ Research Associate/ Senior/Principal Investigator
University of Pennsylvania
February 2001 - January 2010
Physician & Research/Teaching Associate (Physiology)
University of Novi Sad
October 1999 - February 2001
Education
M.S. (Psychology)
Centenary College of New Jersey
September 2023 - May 2025
MBA (Business)
Fitchburg State University
March 2018 - October 2020
Ph.D. -Neuroscience (Physiology)
University of Novi Sad
October 2005 - April 2009
M.Sc. (Physiology )
University of Novi Sad
October 1999 - September 2003
M.D. (Faculty of Medicine)
University of Novi Sad
October 1992 - October 1999
Certifications
- Certification details not provided.
Publications
JOURNAL ARTICLE
Sasha Bogdanovich, Emidio E. Pistilli, Tejvir S. Khurana (2026). Age-Dependent Effect of Myostatin Blockade in the mdx Mouse Model of Duchenne Muscular Dystrophy (DMD) . Muscles.
Sasha Bogdanovich, Emidio E. Pistilli, Tejvir S. Khurana (2026). Age-Dependent Effect of Myostatin Blockade in the <i>mdx</i> Mouse Model of Duchenne Muscular Dystrophy (DMD) . Muscles.
(2026). ACE-031, a soluble activin type IIB receptor, increases muscle mass and strength in the common marmoset (Callithrix jacchus) . PLOS ONE.
(2025). ACE-031, a Soluble Activin Type IIB Receptor, Increases Muscle Mass and Strength in the Common Marmoset (Callithrix jacchus) . bioRxiv.
(2025). I Cannot Sleep!! . PHYSICIAN ASSISTANT CLINICS.
(2025). Phase 1 Trial in Healthy Participants of KER-065, Modified Activin Receptor Ligand Trap, Support Development in Duchenne Muscular Dystrophy (DMD) and Bone Disorders. JOURNAL OF BONE AND MINERAL RESEARCH.
(2025). Phase 1 trial in healthy participants of KER-065, modified activin receptor ligand trap, support development in DMD and other neuromuscular disorders . NEUROMUSCULAR DISORDERS.
(2024). Confirmed Disability Improvement and Progression in Nonactive Progressive Multiple Sclerosis Patients in a Real-World Registry. MULTIPLE SCLEROSIS JOURNAL.
(2023). A Fully Enrolled, Novel, Patient-Centred Real-World Evidence Study Designed to Better Understand Active and Nonactive Progressive Multiple Sclerosis Using Health Records in the United States. MULTIPLE SCLEROSIS JOURNAL.
(2023). Characterizing Mental and Physical Fatigue in Patients With Active or Nonactive Primary or Secondary Progressive Multiple Sclerosis in the United States. MULTIPLE SCLEROSIS JOURNAL.
(2023). Physical and Psychological Impact in Individuals With Active and Nonactive Primary and Secondary Progressive Multiple Sclerosis in the United States. MULTIPLE SCLEROSIS JOURNAL.
(2023). Physician-reported Cognitive Symptoms in Patients with Active and Nonactive Primary or Secondary Progressive Multiple Sclerosis in a Cross-Sectional Survey in the United States. MULTIPLE SCLEROSIS JOURNAL.
(2023). Treatment Patterns and Unmet Need for Patients with Progressive Multiple Sclerosis in the United States: Survey Results from 2016 to 2021 . NEUROLOGY AND THERAPY.
(2022). A novel, patient-centred real-world evidence study designed to better understand active and non-active progressive multiple sclerosis using health records in the United States. MULTIPLE SCLEROSIS JOURNAL.
(2022). Confirmed disability improvement and sustainability in secondary progressive multiple sclerosis placebo-arm patients. EUROPEAN JOURNAL OF NEUROLOGY.
(2022). Disability Progression and Improvement Among Active and Nonactive Secondary Progressive Multiple Sclerosis Patients in Placebo Arms of Clinical Trials (P1-1.Virtual). NEUROLOGY.
(2022). Disability Progression and Improvement Among Patients With Primary and Secondary Progressive Multiple Sclerosis in Placebo Arms of Clinical Trials. MULTIPLE SCLEROSIS JOURNAL.
(2022). Disability progression of active and nonactive primary and secondary progressive multiple sclerosis patients in the US. EUROPEAN JOURNAL OF NEUROLOGY.
(2022). Treatment Patterns of Patients with Active and Nonactive Primary Progressive Multiple Sclerosis in the United States. MULTIPLE SCLEROSIS JOURNAL.
(2022). Unmet need of current disease-modifying treatments reported by physicians in patients with nonactive secondary progressive multiple sclerosis in the United States. MULTIPLE SCLEROSIS JOURNAL.
(2020). High-throughput identification of post-transcriptional utrophin up-regulators for Duchenne muscle dystrophy (DMD) therapy (vol 10, 2132, 2020) . SCIENTIFIC REPORTS.
(2020). High-throughput identification of post-transcriptional utrophin upregulators for Duchenne muscle dystrophy (DMD) therapy . SCIENTIFIC REPORTS.
(2017). Abnormal Muscle Pathology and Physiology . CARDIOSKELETAL MYOPATHIES IN CHILDREN AND YOUNG ADULTS.
(2016). Human IgG1 antibodies suppress angiogenesis in a target-independent manner . SIGNAL TRANSDUCTION AND TARGETED THERAPY.
(2016). Intravenous immune globulin suppresses angiogenesis in mice and humans . SIGNAL TRANSDUCTION AND TARGETED THERAPY.
(2016). Overexpression of Latent TGFβ Binding Protein 4 in Muscle Ameliorates Muscular Dystrophy through Myostatin and TGFβ . PLOS GENETICS.
(2014). A Mouse Model for Dominant Collagen VI Disorders . JOURNAL OF BIOLOGICAL CHEMISTRY.
(2014). DICER1/<i>Alu</i> RNA dysmetabolism induces Caspase-8-mediated cell death in age-related macular degeneration . PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA.
(2014). Excess SMAD signaling contributes to heart and muscle dysfunction in muscular dystrophy . HUMAN MOLECULAR GENETICS.
(2014). Human therapeutic monoclonal antibodies inhibit corneal neovascularization via FcγRI in a target-independent manner. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE.
(2014). IL-18 is not therapeutic for neovascular age-related macular degeneration . NATURE MEDICINE.
(2014). Intravenous immunoglobulin treatment inhibits choroidal and corneal neovascularization via FcyR1. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE.
(2014). Targeting latent TGFβ release in muscular dystrophy . SCIENCE TRANSLATIONAL MEDICINE.
(2014). The Fc fragments of Bevacizumab or IVIG suppress choroidal neovascularization. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE.
(2013). COL6A3 Protein Deficiency in Mice Leads to Muscle and Tendon Defects Similar to Human Collagen VI Congenital Muscular Dystrophy . JOURNAL OF BIOLOGICAL CHEMISTRY.
(2012). DICER1 Loss and <i>Alu</i> RNA Induce Age-Related Macular Degeneration via the NLRP3 Inflammasome and MyD88 . CELL.
(2012). ERK1/2 activation is a therapeutic target in age-related macular degeneration . PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA.
(2012). Inhibition of Choroidal and Corneal Pathologic Neovascularization by <i>Plgf1</i>-<i>de</i> Gene Transfer . INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE.
(2012). Short-interfering RNAs Induce Retinal Degeneration via TLR3 and IRF3 . MOLECULAR THERAPY.
(2011). Biglycan recruits utrophin to the sarcolemma and counters dystrophic pathology in mdx mice . PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA.
(2011). DICER1 deficit induces <i>Alu</i> RNA toxicity in age-related macular degeneration . NATURE.
(2011). Loss of IL-15 receptor α alters the endurance, fatigability, and metabolic characteristics of mouse fast skeletal muscles . JOURNAL OF CLINICAL INVESTIGATION.
(2011). Targeting the Activin Type IIB Receptor to Improve Muscle Mass and Function in the <i>mdx</i> Mouse Model of Duchenne Muscular Dystrophy . AMERICAN JOURNAL OF PATHOLOGY.
(2010). Differential Expression of Utrophin-A and -B Promoters in the Central Nervous System (CNS) of Normal and Dystrophic <i>mdx</i> Mice . BRAIN PATHOLOGY.
(2010). Pretreatment with a soluble activin type IIB receptor/Fc fusion protein improves hypoxia-induced muscle dysfunction . AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY.
(2009). Long-term activin receptor type IIB inhibition improves strength and function of dystrophic muscle . NEUROMUSCULAR DISORDERS.
(2009). The effects of a soluble activin type IIB receptor on obesity and insulin sensitivity . INTERNATIONAL JOURNAL OF OBESITY.
(2009). Transcriptional and functional differences in stem cell populations isolated from extraocular and limb muscles . PHYSIOLOGICAL GENOMICS.
(2008). Myostatin blockade improves function but not histopathology in a murine model of limb-girdle muscular dystrophy 2C . MUSCLE & NERVE.
(2008). Role of hypoxia in muscle function and muscular dystrophy. FASEB JOURNAL.
(2008). Treatment with a soluble Activin type IIB receptor increases muscle size and strength of dystrophin deficient muscle . NEUROMUSCULAR DISORDERS.
(2007). Identification and characterization of layer-specific differences in extraocular muscle M-bands . INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE.
(2006). Corneal avascularity is due to soluble VEGF receptor-1 . NATURE.
(2006). Role of hypoxia-mediated muscle damage in neuromuscular disorders. NEUROMUSCULAR DISORDERS.
(2005). Myostatin propeptide-mediated amelioration of dystrophic pathophysiology . FASEB JOURNAL.
(2005). Molecular and ultrastructural characterization of adult rat extraocular muscle (EOM) M-lines. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE.
(2005). Structural details of rat extraocular muscles and three-dimensional reconstruction of the rat inferior rectus muscle and muscle-pulley interface . VISION RESEARCH.
(2004). Anti-oxidative response of carbonic anhydrase III in skeletal muscle . IUBMB LIFE.
(2004). Heregulin ameliorates the dystrophic phenotype in <i>mdx</i> mice . PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA.
(2004). Layer-specific differences of gene expression in extraocular muscles identified by laser-capture microscopy . PHYSIOLOGICAL GENOMICS.
(2004). Therapeutics for Duchenne muscular dystrophy: current approaches and future directions . JOURNAL OF MOLECULAR MEDICINE-JMM.
(2003). Three dimensional reconstruction and detailed structural analysis of the extraocular muscle-pulley interface. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE.
(2002). Expression profiling reveals metabolic and structural components of extraocular muscles. JOURNAL OF THE NEUROLOGICAL SCIENCES.
(2002). Expression profiling reveals metabolic and structural components of extraocular muscles . PHYSIOLOGICAL GENOMICS.
(2002). Expression profiling reveals metabolic and structural components of extraocular muscles. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE.
(2002). Functional improvement of dystrophic muscle by myostatin blockade . NATURE.
(2002). Myostatin (GDF8) blockage improves muscle function in MDX mouse. JOURNAL OF THE NEUROLOGICAL SCIENCES.
Ratings and Comments
Total Projects Awarded:
Comments: